

Jennifer G Robinson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4517658/publications.pdf>

Version: 2024-02-01

310
papers

36,383
citations

10956

71
h-index

3257

185
g-index

321
all docs

321
docs citations

321
times ranked

36224
citing authors

#	ARTICLE	IF	CITATIONS
1	2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. <i>Circulation</i> , 2014, 129, S1-45.	1.6	4,842
2	2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2889-2934.	1.2	3,414
3	2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2935-2959.	1.2	3,277
4	2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. <i>Circulation</i> , 2014, 129, S49-73.	1.6	2,823
5	Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2015, 372, 1489-1499.	13.9	1,838
6	Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2015, 372, 1500-1509.	13.9	1,352
7	Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease. <i>New England Journal of Medicine</i> , 2014, 371, 22-31.	13.9	936
8	Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association. <i>Circulation</i> , 2017, 136, e1-e23.	1.6	884
9	Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 2144-2153.	13.9	596
10	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet</i> , 2015, 385, 351-361.	6.3	562
11	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. <i>Journal of Clinical Lipidology</i> , 2011, 5, 133-140.	0.6	483
12	Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1870.	3.8	422
13	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. <i>Journal of Clinical Lipidology</i> , 2011, 5, S1-S8.	0.6	406
14	Noninvasive Pulse Wave Analysis for the Early Detection of Vascular Disease. <i>Hypertension</i> , 1995, 26, 503-508.	1.3	405
15	Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1855-1862.	1.2	397
16	Optimism, Cynical Hostility, and Incident Coronary Heart Disease and Mortality in the Women's Health Initiative. <i>Circulation</i> , 2009, 120, 656-662.	1.6	368
17	Cognitive Function in a Randomized Trial of Evolocumab. <i>New England Journal of Medicine</i> , 2017, 377, 633-643.	13.9	366
18	Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1566.	3.8	339

#	ARTICLE	IF	CITATIONS
19	Meta-Analysis of the Relationship Between Non-HDL Cholesterol Reduction and Coronary Heart Disease Risk. <i>Journal of the American College of Cardiology</i> , 2009, 53, 316-322.	1.2	327
20	Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. <i>American Heart Journal</i> , 2015, 169, 906-915.e13.	1.2	294
21	Association of Low-Frequency and Rare Coding-Sequence Variants with Blood Lipids and Coronary Heart Disease in 56,000 Whites and Blacks. <i>American Journal of Human Genetics</i> , 2014, 94, 223-232.	2.6	287
22	Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. <i>Circulation</i> , 2019, 140, e673-e691.	1.6	282
23	Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1575-1579.	1.2	258
24	Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements. <i>Clinical Trials</i> , 2008, 5, 240-247.	0.7	229
25	Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24-week, double-blind, randomized Phase 3 trial. <i>International Journal of Cardiology</i> , 2014, 176, 55-61.	0.8	229
26	Comparison of the Framingham and Reynolds Risk Scores for Global Cardiovascular Risk Prediction in the Multiethnic Women's Health Initiative. <i>Circulation</i> , 2012, 125, 1748-1756.	1.6	205
27	Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3140-3148.	1.8	198
28	Whole-Exome Sequencing Identifies Rare and Low-Frequency Coding Variants Associated with LDL Cholesterol. <i>American Journal of Human Genetics</i> , 2014, 94, 233-245.	2.6	193
29	Maternal Hyperlipidemia and the Risk of Preeclampsia: a Meta-Analysis. <i>American Journal of Epidemiology</i> , 2014, 180, 346-358.	1.6	190
30	Electronic health records based phenotyping in next-generation clinical trials: a perspective from the NIH Health Care Systems Collaboratory: Table 1. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2013, 20, e226-e231.	2.2	188
31	Antiatherosclerotic and Antithrombotic Effects of Omega-3 Fatty Acids. <i>American Journal of Cardiology</i> , 2006, 98, 39-49.	0.7	168
32	Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab. <i>Journal of the American College of Cardiology</i> , 2017, 69, 471-482.	1.2	166
33	Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment. <i>Menopause</i> , 2001, 8, 17-26.	0.8	165
34	Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Synopsis of the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline. <i>Annals of Internal Medicine</i> , 2014, 160, 339-343.	2.0	164
35	Long-Term Effects on Cognitive Function of Postmenopausal Hormone Therapy Prescribed to Women Aged 50 to 55 Years. <i>JAMA Internal Medicine</i> , 2013, 173, 1429.	2.6	161
36	Sleep duration, cognitive decline, and dementia risk in older women. <i>Alzheimer's and Dementia</i> , 2016, 12, 21-33.	0.4	156

#	ARTICLE	IF	CITATIONS
37	Sex Differences in the Use of Statins in Community Practice. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005562.	0.9	155
38	Safety of Aggressive Lipid Management. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1753-1762.	1.2	144
39	Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies. <i>PLoS Medicine</i> , 2018, 15, e1002670.	3.9	143
40	No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. <i>European Heart Journal</i> , 2016, 37, 2981-2989.	1.0	142
41	Patient-Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e011765.	1.6	139
42	Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 403-410.	5.5	133
43	Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies. <i>Nature Communications</i> , 2021, 12, 2329.	5.8	132
44	Resilience to chronic stress is mediated by noradrenergic regulation of dopamine neurons. <i>Nature Neuroscience</i> , 2016, 19, 560-563.	7.1	130
45	Determining When to Add Nonstatin Therapy. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2412-2421.	1.2	125
46	A Large-Scale Multi-ancestry Genome-wide Study Accounting for Smoking Behavior Identifies Multiple Significant Loci for Blood Pressure. <i>American Journal of Human Genetics</i> , 2018, 102, 375-400.	2.6	123
47	Cardiovascular Disease and Cognitive Decline in Postmenopausal Women: Results From the Women's Health Initiative Memory Study. <i>Journal of the American Heart Association</i> , 2013, 2, e000369.	1.6	118
48	Effect of Alirocumab on Lipoprotein(a) Over 1.5 Years (from the Phase 3 ODYSSEY Program). <i>American Journal of Cardiology</i> , 2017, 119, 40-46.	0.7	116
49	Racial/Ethnic and Gender Gaps in the Use of and Adherence to Evidence-Based Preventive Therapies Among Elderly Medicare Part D Beneficiaries After Acute Myocardial Infarction. <i>Circulation</i> , 2014, 129, 754-763.	1.6	115
50	Genome-wide Characterization of Shared and Distinct Genetic Components that Influence Blood Lipid Levels in Ethnically Diverse Human Populations. <i>American Journal of Human Genetics</i> , 2013, 92, 904-916.	2.6	113
51	Influence of Type 2 Diabetes on Brain Volumes and Changes in Brain Volumes. <i>Diabetes Care</i> , 2013, 36, 90-97.	4.3	113
52	Trans-Ethnic Fine-Mapping of Lipid Loci Identifies Population-Specific Signals and Allelic Heterogeneity That Increases the Trait Variance Explained. <i>PLoS Genetics</i> , 2013, 9, e1003379.	1.5	112
53	Multi-ancestry genome-wide gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. <i>Nature Genetics</i> , 2019, 51, 636-648.	9.4	112
54	Effect of Long-Chain n-3 Fatty Acids and Lutein+Zeaxanthin Supplements on Cardiovascular Outcomes. <i>JAMA Internal Medicine</i> , 2014, 174, 763.	2.6	110

#	ARTICLE	IF	CITATIONS
55	Meta-Analysis of Comparison of Effectiveness of Lowering Apolipoprotein B Versus Low-Density Lipoprotein Cholesterol and Nonhigh-Density Lipoprotein Cholesterol for Cardiovascular Risk Reduction in Randomized Trials. <i>American Journal of Cardiology</i> , 2012, 110, 1468-1476.	0.7	108
56	Optogenetic Activation of Septal Glutamatergic Neurons Drive Hippocampal Theta Rhythms. <i>Journal of Neuroscience</i> , 2016, 36, 3016-3023.	1.7	108
57	Treatment of adults with Familial Hypercholesterolemia and evidence for treatment: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2011, 5, S18-S29.	0.6	107
58	Genome-wide Association and Population Genetic Analysis of C-Reactive Protein in African American and Hispanic American Women. <i>American Journal of Human Genetics</i> , 2012, 91, 502-512.	2.6	107
59	Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. <i>European Heart Journal</i> , 2010, 31, 480-488.	1.0	106
60	Multimarker Prediction of Coronary Heart Disease Risk. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2080-2091.	1.2	105
61	Effect of 5 y of calcium plus vitamin D supplementation on change in circulating lipids: results from the Women's Health Initiative. <i>American Journal of Clinical Nutrition</i> , 2010, 91, 894-899.	2.2	101
62	Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use. <i>JAMA Cardiology</i> , 2018, 3, 739.	3.0	94
63	Fatty acid consumption and risk of fracture in the Women's Health Initiative. <i>American Journal of Clinical Nutrition</i> , 2010, 92, 1452-1460.	2.2	89
64	Management of Familial Hypercholesterolemia: A Review of the Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Managed Care Pharmacy</i> , 2013, 19, 139-149.	2.2	88
65	Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 281-289.	1.3	86
66	Multiancestry Genome-Wide Association Study of Lipid Levels Incorporating Gene-Alcohol Interactions. <i>American Journal of Epidemiology</i> , 2019, 188, 1033-1054.	1.6	85
67	Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset. <i>Human Molecular Genetics</i> , 2014, 23, 1957-1963.	1.4	82
68	Lack of Association Between 25(OH)D Levels and Incident Type 2 Diabetes in Older Women. <i>Diabetes Care</i> , 2011, 34, 628-634.	4.3	81
69	Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials. <i>American Journal of Cardiology</i> , 2016, 118, 1805-1811.	0.7	80
70	Curing Atherosclerosis Should Be the Next Major Cardiovascular Prevention Goal. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2779-2785.	1.2	77
71	Use of Medicare Data to Identify Coronary Heart Disease Outcomes in the Women's Health Initiative. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 157-162.	0.9	76
72	The impact of birth weight on cardiovascular disease risk in the Women's Health Initiative. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 239-245.	1.1	76

#	ARTICLE	IF	CITATIONS
73	Challenges and Opportunities for the Prevention and Treatment of Cardiovascular Disease Among Young Adults: Report From a National Heart, Lung, and Blood Institute Working Group. <i>Journal of the American Heart Association</i> , 2020, 9, e016115.	1.6	75
74	Soy Protein Intake by Perimenopausal Women Does Not Affect Circulating Lipids and Lipoproteins or Coagulation and Fibrinolytic Factors. <i>Journal of Nutrition</i> , 2001, 131, 2280-2287.	1.3	74
75	Evaluation of the MetaboChip Genotyping Array in African Americans and Implications for Fine Mapping of GWAS-Identified Loci: The PAGE Study. <i>PLoS ONE</i> , 2012, 7, e35651.	1.1	71
76	Efficacy and Safety of Alirocumab 150mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	71
77	Fish Intake and the Risk of Incident Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 404-413.	1.6	68
78	Low-fat dietary pattern and cardiovascular disease: results from the Women's Health Initiative randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2017, 106, 35-43.	2.2	67
79	Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. <i>Journal of the American Heart Association</i> , 2018, 7, e009778.	1.6	67
80	Conjugated equine estrogens and peripheral arterial disease risk: The Women's Health Initiative. <i>American Heart Journal</i> , 2006, 152, 170-176.	1.2	66
81	Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1543-1554.	1.2	65
82	Multi-ancestry study of blood lipid levels identifies four loci interacting with physical activity. <i>Nature Communications</i> , 2019, 10, 376.	5.8	64
83	Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients With Hypercholesterolemia and the Metabolic Syndrome (from the VYMET Study). <i>American Journal of Cardiology</i> , 2009, 103, 1694-1702.	0.7	62
84	Vitamin D Intake and Season Modify the Effects of the GC and CYP2R1 Genes on 25-Hydroxyvitamin D Concentrations. <i>Journal of Nutrition</i> , 2013, 143, 17-26.	1.3	62
85	Red blood cell polyunsaturated fatty acids and mortality in the Women's Health Initiative Memory Study. <i>Journal of Clinical Lipidology</i> , 2017, 11, 250-259.e5.	0.6	59
86	Nonstatin Low-Density Lipoprotein "Lowering Therapy and Cardiovascular Risk Reduction" Statement From the American Heart Association Council. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2269-2280.	1.1	58
87	Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women's Health Initiative. <i>JAMA Internal Medicine</i> , 2018, 178, 1231.	2.6	58
88	Birth weight and subsequent risk of cancer. <i>Cancer Epidemiology</i> , 2014, 38, 538-543.	0.8	57
89	Correcting the Effects of 20°C Storage and Aliquot Size on Erythrocyte Fatty Acid Content in the Women's Health Initiative. <i>Lipids</i> , 2012, 47, 835-846.	0.7	56
90	Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly?. <i>Stroke</i> , 2007, 38, 441-450.	1.0	55

#	ARTICLE	IF	CITATIONS
91	The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. <i>European Heart Journal</i> , 2015, 36, 2110-2118.	1.0	55
92	Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry. <i>American Heart Journal</i> , 2017, 193, 84-92.	1.2	55
93	A Prospective Study of the Effect of Hypertension and Baseline Blood Pressure on Cognitive Decline and Dementia in Postmenopausal Women: The Women's Health Initiative Memory Study. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 1449-1458.	1.3	53
94	Lipoprotein Particle Concentrations May Explain the Absence of Coronary Protection in the Women's Health Initiative Hormone Trials. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1666-1671.	1.1	53
95	Effects of Postmenopausal Hormone Therapy on Incident Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 1108-1116.	2.1	53
96	Relationship of Hypertension, Blood Pressure, and Blood Pressure Control With White Matter Abnormalities in the Women's Health Initiative Memory Study (WHIMS) MRI Trial. <i>Journal of Clinical Hypertension</i> , 2010, 12, 203-212.	1.0	51
97	Prospective association of vitamin D concentrations with mortality in postmenopausal women: results from the Women's Health Initiative (WHI). <i>American Journal of Clinical Nutrition</i> , 2011, 94, 1471-1478.	2.2	51
98	n-3 Fatty Acid Biomarkers and Incident Type 2 Diabetes: An Individual Participant-Level Pooling Project of 20 Prospective Cohort Studies. <i>Diabetes Care</i> , 2021, 44, 1133-1142.	4.3	50
99	Cardiovascular Risk in Women With Non-Specific Chest Pain (from the Women's Health Initiative) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10 TF</i>	0.7	49
100	Association of fried food consumption with all cause, cardiovascular, and cancer mortality: prospective cohort study. <i>BMJ: British Medical Journal</i> , 2019, 364, k5420.	2.4	49
101	Low-fat dietary pattern and lipoprotein risk factors: the Women's Health Initiative Dietary Modification Trial. <i>American Journal of Clinical Nutrition</i> , 2010, 91, 860-874.	2.2	48
102	Self-Reported Snoring and Risk of Cardiovascular Disease Among Postmenopausal Women (from the) <i>Tj ETQq0 0 0 rgBT /Overlock 10 TF</i>	0.7	48
103	Influence of Cardiovascular Risk Communication Tools and Presentation Formats on Patient Perceptions and Preferences. <i>JAMA Cardiology</i> , 2018, 3, 1192.	3.0	48
104	Lipid-lowering effects of statins: a comparative review. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1701-1714.	0.9	47
105	Statins and diabetes risk. <i>Current Opinion in Lipidology</i> , 2015, 26, 228-235.	1.2	47
106	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 19-31.	1.6	46
107	Cardiovascular Health and Incident Cardiovascular Disease and Cancer. <i>American Journal of Preventive Medicine</i> , 2016, 50, 236-240.	1.6	45
108	Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2019, 13, 525-537.	0.6	45

#	ARTICLE	IF	CITATIONS
109	A "poly-portfolio" for secondary prevention: A strategy to reduce subsequent events by up to 97% over five years. <i>American Journal of Cardiology</i> , 2005, 95, 373-378.	0.7	44
110	Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. <i>Expert Review of Cardiovascular Therapy</i> , 2006, 4, 461-476.	0.6	44
111	Joint Associations of Diet, Lifestyle, and Genes with Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2015, 122, 2286-2294.	2.5	44
112	Identifying Patients for Aggressive Cholesterol Lowering: The Risk Curve Concept. <i>American Journal of Cardiology</i> , 2006, 98, 1405-1408.	0.7	43
113	Association Between Vitamin D Status and Age-Related Macular Degeneration by Genetic Risk. <i>JAMA Ophthalmology</i> , 2015, 133, 1171.	1.4	43
114	Omega-3 Fatty Acids and Cognitive Function in Women. <i>Women's Health</i> , 2010, 6, 119-134.	0.7	41
115	Efficacy and Safety of Alirocumab as Add-on Therapy in High-Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies. <i>Clinical Cardiology</i> , 2014, 37, 597-604.	0.7	41
116	Diet Drink Consumption and the Risk of Cardiovascular Events: A Report from the Women's Health Initiative. <i>Journal of General Internal Medicine</i> , 2015, 30, 462-468.	1.3	41
117	Racial and Ethnic Differences in Incident Hospitalized Heart Failure in Postmenopausal Women. <i>Circulation</i> , 2012, 126, 688-696.	1.6	40
118	A novel telephone-based system for management of secondary prevention to a low-density lipoprotein cholesterol ≥ 100 mg/dl. <i>American Journal of Cardiology</i> , 2000, 85, 305-308.	0.7	39
119	Enrollment in a Brain Magnetic Resonance Study: Results From the Women's Health Initiative Memory Study Magnetic Resonance Imaging Study (WHIMS-MRI). <i>Academic Radiology</i> , 2007, 14, 603-612.	1.3	39
120	Omega-3 fatty acids and domain-specific cognitive aging. <i>Neurology</i> , 2013, 81, 1484-1491.	1.5	38
121	Fatty acids in the de novo lipogenesis pathway and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies. <i>PLoS Medicine</i> , 2020, 17, e1003102.	3.9	38
122	Statins, Angiotensin-Converting Enzyme Inhibitors, and Physical Performance in Older Women. <i>Journal of the American Geriatrics Society</i> , 2012, 60, 2206-2214.	1.3	37
123	Biomimetic strategies for engineering composite tissues. <i>Current Opinion in Biotechnology</i> , 2016, 40, 64-74.	3.3	37
124	Erythrocyte omega-3 fatty acids are inversely associated with incident dementia: Secondary analyses of longitudinal data from the Women's Health Initiative Memory Study (WHIMS). <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2017, 121, 68-75.	1.0	37
125	First trimester prenatal screening biomarkers and gestational diabetes mellitus: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0201319.	1.1	37
126	Management of the Patient with Statin Intolerance. <i>Current Atherosclerosis Reports</i> , 2010, 12, 48-57.	2.0	36

#	ARTICLE	IF	CITATIONS
127	Dalcetrapib: a review of Phase II data. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 795-805.	1.9	36
128	Evidence-Based Policy Making: Assessment of the American Heart Association's Strategic Policy Portfolio. <i>Circulation</i> , 2016, 133, e615-53.	1.6	36
129	The Cross-Sectional Relationship Between Body Mass Index, Waist-Hip Ratio, and Cognitive Performance in Postmenopausal Women Enrolled in the Women's Health Initiative. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 1427-1432.	1.3	35
130	Models for Describing Relations Among the Various Statin Drugs, Low-Density Lipoprotein Cholesterol Lowering, Pleiotropic Effects, and Cardiovascular Risk—Conflicts of interest: In the past 2 years, Dr. Robinson has received grants from Abbott Laboratories, Abbott Park, Illinois, Astra-Zeneca, Wilmington, Delaware, Bristol-Myers Squibb, Princeton, New Jersey, GlaxoSmithKline, Pittsburgh, Pennsylvania, Hoffman La Roche, Basel, Switzerland, Merck & Company, West Point, Pennsylvania, Pfizer, New York, New York. <i>American Journal of Cardiology</i> , 2008, 101, 1009-1015.	0.7	34
131	Affecting Behavior Change in Individuals With Diabetes Findings From the Study to Help Improve Early Evaluation and Management of Risk Factors Leading to Diabetes (SHIELD). <i>The Diabetes Educator</i> , 2008, 34, 1025-1036.	2.6	34
132	Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. <i>Journal of Clinical Lipidology</i> , 2010, 4, 483-490.	0.6	34
133	Evaluation of the American Heart Association Cardiovascular Disease Prevention Guideline for Women. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 128-134.	0.9	33
134	Red Blood Cell Fatty Acids and Incident Diabetes Mellitus in the Women's Health Initiative Memory Study. <i>PLoS ONE</i> , 2016, 11, e0147894.	1.1	33
135	PCSK9 Inhibitors and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2015, 373, 773-775.	13.9	32
136	Can Biomarkers Identify Women at Increased Stroke Risk? The Women's Health Initiative Hormone Trials. <i>PLOS Clinical Trials</i> , 2007, 2, e28.	3.5	31
137	Atherosclerosis profile and incidence of cardiovascular events: a population-based survey. <i>BMC Cardiovascular Disorders</i> , 2009, 9, 46.	0.7	31
138	Maternal dyslipidemia and risk for preterm birth. <i>PLoS ONE</i> , 2018, 13, e0209579.	1.1	31
139	A multi-ancestry genome-wide study incorporating gene-smoking interactions identifies multiple new loci for pulse pressure and mean arterial pressure. <i>Human Molecular Genetics</i> , 2019, 28, 2615-2633.	1.4	31
140	Omega-3 fatty acid biomarkers and subsequent depressive symptoms. <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 747-757.	1.3	30
141	Fine-mapping of lipid regions in global populations discovers ethnic-specific signals and refines previously identified lipid loci. <i>Human Molecular Genetics</i> , 2016, 25, 5500-5512.	1.4	29
142	Starting Primary Prevention Earlier With Statins. <i>American Journal of Cardiology</i> , 2014, 114, 1437-1442.	0.7	28
143	Future issues, public policy, and public awareness of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2011, 5, S46-S51.	0.6	27
144	Clinical Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Disease Prediction in a Multiethnic Cohort of Women. <i>Clinical Chemistry</i> , 2012, 58, 1352-1363.	1.5	27

#	ARTICLE	IF	CITATIONS
145	ApoB in clinical care: Pro and Con. <i>Atherosclerosis</i> , 2019, 282, 169-175.	0.4	27
146	Changes in Statin Adherence Following an Acute Myocardial Infarction Among Older Adults: Patient Predictors and the Association With Follow-up With Primary Care Providers and/or Cardiologists. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	26
147	Consistent LDL response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. <i>Clinical Cardiology</i> , 2018, 41, 1328-1335.	0.7	25
148	Alcohol Consumption, Hypertension, and Total Mortality Among Women. <i>American Journal of Hypertension</i> , 2009, 22, 1212-1218.	1.0	24
149	Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years. <i>Journal of Clinical Lipidology</i> , 2017, 11, 986-997.	0.6	24
150	Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004249.	0.9	24
151	Development and validation of a clinical model for preconception and early pregnancy risk prediction of gestational diabetes mellitus in nulliparous women. <i>PLoS ONE</i> , 2019, 14, e0215173.	1.1	24
152	Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65-74 and 75 years and older. <i>Aging Health</i> , 2007, 3, 691-705.	0.3	23
153	Depressive Symptoms and Longitudinal Changes in Cognition. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2014, 27, 94-102.	1.2	23
154	Moving Toward the Next Paradigm for Cardiovascular Prevention. <i>Circulation</i> , 2016, 133, 1533-1536.	1.6	23
155	Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). <i>Journal of Clinical Lipidology</i> , 2011, 5, 474-482.	0.6	22
156	Overview of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. <i>Future Cardiology</i> , 2014, 10, 149-152.	0.5	22
157	Geographic Variation in Statin Use for Complex Acute Myocardial Infarction Patients. <i>Medical Care</i> , 2014, 52, S37-S44.	1.1	22
158	Insulin Resistance and Risk of Cardiovascular Disease in Postmenopausal Women. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 309-316.	0.9	21
159	The effects of transdermal testosterone and oestrogen therapy on dry eye in postmenopausal women: a randomised, placebo-controlled, pilot study. <i>British Journal of Ophthalmology</i> , 2017, 101, 926-932.	2.1	21
160	Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies. <i>Diabetes Therapy</i> , 2018, 9, 1317-1334.	1.2	21
161	Simvastatin: present and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2159-2127.	0.9	20
162	Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry. <i>American Heart Journal</i> , 2015, 170, 865-871.	1.2	20

#	ARTICLE	IF	CITATIONS
163	Comparison of Cardiovascular Risk Factors for Coronary Heart Disease and Stroke Type in Women. <i>Journal of the American Heart Association</i> , 2018, 7, e007514.	1.6	20
164	Patient-Perceived Versus Actual Risk of Cardiovascular Disease and Associated Willingness to Consider and Use Prevention Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006548.	0.9	20
165	Elderly Women Diagnosed with Nonspecific Chest Pain May Be at Increased Cardiovascular Risk. <i>Journal of Women's Health</i> , 2006, 15, 1151-1160.	1.5	19
166	What Is the Role of Advanced Lipoprotein Analysis in Practice?. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2607-2615.	1.2	19
167	Comparison of Lifestyle-Based and Traditional Cardiovascular Disease Prediction in a Multiethnic Cohort of Nonsmoking Women. <i>Circulation</i> , 2014, 130, 1466-1473.	1.6	19
168	Genetic Predisposition to Dyslipidemia and Risk of Preeclampsia. <i>American Journal of Hypertension</i> , 2015, 28, 915-923.	1.0	19
169	Genetic Risk Score for Essential Hypertension and Risk of Preeclampsia. <i>American Journal of Hypertension</i> , 2016, 29, 17-24.	1.0	19
170	It's Not Too Late to Improve Statin Adherence: Association Between Changes in Statin Adherence from Before to After Acute Myocardial Infarction and All-Cause Mortality. <i>Journal of the American Heart Association</i> , 2019, 8, e011378.	1.6	19
171	Should We Use PPAR Agonists to Reduce Cardiovascular Risk?. <i>PPAR Research</i> , 2008, 2008, 1-13.	1.1	18
172	Chart validation of inpatient ICD-9-CM administrative diagnosis codes for acute myocardial infarction (AMI) among intravenous immune globulin (IGIV) users in the Sentinel Distributed Database. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 398-404.	0.9	18
173	The rationale, design, and baseline characteristics of the Women's Health Initiative Memory Study of Younger Women (WHIMS-Y). <i>Brain Research</i> , 2013, 1514, 3-11.	1.1	17
174	The Relationship Between Serum 25-Hydroxyvitamin D Levels and Nuclear Cataract in the Carotenoid Age-Related Eye Study (CAREDS), an Ancillary Study of the Women's Health Initiative. , 2015, 56, 4221.		17
175	New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 119-127.	1.4	17
176	Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. <i>American Heart Journal</i> , 2019, 214, 113-124.	1.2	17
177	Accumulating Evidence for Statins in Primary Prevention. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2405.	3.8	16
178	Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH. <i>American Journal of Medicine</i> , 2016, 129, 753.e13-753.e22.	0.6	16
179	Correlates of Successful Aging in Racial and Ethnic Minority Women Age 80 Years and Older: Findings from the Women's Health Initiative. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, S87-S99.	1.7	16
180	Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. <i>Journal of Clinical Lipidology</i> , 2013, 7, 292-303.	0.6	15

#	ARTICLE	IF	CITATIONS
181	Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 586-590.	1.1	15
182	More Dynamic Than You Think: Hidden Aspects of Decision-Making. <i>Administrative Sciences</i> , 2017, 7, 23.	1.5	15
183	It Is Now Time to Focus on Risk Before Age 40. <i>Journal of the American College of Cardiology</i> , 2019, 74, 342-345.	1.2	15
184	Early pregnancy prediction of gestational diabetes mellitus risk using prenatal screening biomarkers in nulliparous women. <i>Diabetes Research and Clinical Practice</i> , 2020, 163, 108139.	1.1	15
185	Lipid-Lowering Therapy for the Primary Prevention of Cardiovascular Disease in the Elderly. <i>Drugs and Aging</i> , 2009, 26, 917-931.	1.3	14
186	Lipid-lowering effects of ezetimibe and simvastatin in combination. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 131-145.	0.6	14
187	Prevalent But Moderate Variation Across Small Geographic Regions in Patient Nonadherence to Evidence-based Preventive Therapies in Older Adults After Acute Myocardial Infarction. <i>Medical Care</i> , 2014, 52, 185-193.	1.1	14
188	Subclinical Hypothyroidism and Risk for Incident Ischemic Stroke Among Postmenopausal Women. <i>Thyroid</i> , 2014, 24, 1210-1217.	2.4	14
189	Progenitor Cells of the Mandibular Condylar Cartilage. <i>Current Molecular Biology Reports</i> , 2015, 1, 110-114.	0.8	14
190	Embedding clinical interventions into observational studies. <i>Contemporary Clinical Trials</i> , 2016, 46, 100-105.	0.8	14
191	The Relationship of Cardiovascular Disease to Physical Functioning in Women Surviving to Age 80 and Above in the Women's Health Initiative. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, S42-S53.	1.7	14
192	New insights into managing symptoms during statin therapy. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 390-394.	1.6	14
193	Association of Body Mass Index With Colorectal Cancer Risk by Genome-Wide Variants. <i>Journal of the National Cancer Institute</i> , 2021, 113, 38-47.	3.0	14
194	Effectiveness of a Novel 3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia. <i>JAMA Network Open</i> , 2022, 5, e2141898.	2.8	14
195	Update on PPAR agonists: The clinical significance of FIELD and PROACTIVE. <i>Current Atherosclerosis Reports</i> , 2007, 9, 64-71.	2.0	13
196	Atherosclerosis stabilization with PCSK-9 inhibition: An evolving concept for cardiovascular prevention. <i>Atherosclerosis</i> , 2015, 243, 593-597.	0.4	13
197	Association Between Preadmission Functional Status and Use and Effectiveness of Secondary Prevention Medications in Elderly Survivors of Acute Myocardial Infarction. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 526-535.	1.3	13
198	Metabolic syndrome cluster does not provide incremental prognostic information in patients with stable cardiovascular disease: A post hoc analysis of the AIM-HIGH trial. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1201-1211.	0.6	13

#	ARTICLE	IF	CITATIONS
199	Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150Âmg doses. <i>Journal of Clinical Lipidology</i> , 2019, 13, 979-988.e10.	0.6	13
200	Cardiovascular disease (CVD) risk scores, age, or years since menopause to predict cardiovascular disease in the Women's Health Initiative. <i>Menopause</i> , 2021, 28, 610-618.	0.8	13
201	Rationale and Design of <sc>LAPLACE</sc>â€²: A Phase 3, Randomized, Doubleâ€Blind, Placeboâ€and Ezetimibeâ€Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy. <i>Clinical Cardiology</i> , 2014, 37, 195-203.	0.7	12
202	Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 24.	2.0	12
203	Lipid management beyond the guidelines. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 384-389.	1.6	12
204	Can atherosclerosis be cured?. <i>Current Opinion in Lipidology</i> , 2019, 30, 477-484.	1.2	12
205	Prognostic Utility of Risk Enhancers and Coronary Artery Calcium Score Recommended in the 2018 ACC/AHA Multisociety Cholesterol Treatment Guidelines Over the Pooled Cohort Equation: Insights From 3 Large Prospective Cohorts. <i>Journal of the American Heart Association</i> , 2021, 10, e019589.	1.6	12
206	Can We Cure Atherosclerosis?. <i>Reviews in Cardiovascular Medicine</i> , 2018, 19, 20-24.	0.5	12
207	Attitudes About Health and Healthâ€Related Behaviors in Patients With Cardiovascular Disease or at Elevated Risk for Cardiovascular Disease. <i>Preventive Cardiology</i> , 2009, 12, 136-143.	1.1	11
208	Statin Use After Acute Myocardial Infarction by Patient Complexity. <i>Medical Care</i> , 2015, 53, 324-331.	1.1	11
209	Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Nonâ€Familial Hypercholesterolemia. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 165-171.	1.6	11
210	Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e013229.	1.6	11
211	Association Between Different Measures of Blood Pressure and Coronary Artery Calcium in Postmenopausal Women. <i>Hypertension</i> , 2008, 52, 833-840.	1.3	10
212	Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin. <i>Vascular Health and Risk Management</i> , 2008, 5, 31.	1.0	10
213	Another treatment gap: Restarting secondary prevention medications: The Women's Health Initiative. <i>Journal of Clinical Lipidology</i> , 2010, 4, 36-45.	0.6	10
214	Trajectories of positive aging: observations from the women's health initiative study. <i>International Psychogeriatrics</i> , 2014, 26, 1351-1362.	0.6	10
215	Lower might be better â€ It matters how you get there, and in whom. <i>European Heart Journal</i> , 2016, 37, 1380-1383.	1.0	10
216	Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 59-71.	2.3	10

#	ARTICLE	IF	CITATIONS
217	Reticular Pseudodrusen Characteristics and Associations in the Carotenoids in Age-Related Eye Disease Study 2 (CAREDS2), an Ancillary Study of the Women's Health Initiative. <i>Ophthalmology Retina</i> , 2021, 5, 721-729.	1.2	10
218	Clopidogrel and Neuraxial Block. <i>Regional Anesthesia and Pain Medicine</i> , 2010, 35, 115.	1.1	9
219	Exploring the interaction between SNP genotype and postmenopausal hormone therapy effects on stroke risk. <i>Genome Medicine</i> , 2012, 4, 57.	3.6	9
220	2013 ACC/AHA Cholesterol Guideline for Reducing Cardiovascular Risk: What is so Controversial?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 413.	2.0	9
221	Temporal Trends of High-Intensity Statin Therapy Among Veterans Treated With Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	9
222	Measurement of Low-Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry. <i>Journal of the American Heart Association</i> , 2018, 7, e009251.	1.6	9
223	Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport. <i>Future Lipidology</i> , 2007, 2, 285-301.	0.5	8
224	Is it over for ezetimibe?. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 781-783.	0.6	8
225	Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers after an Acute Myocardial Infarction. <i>Pharmacotherapy</i> , 2018, 38, 29-41.	1.2	8
226	The extent to which statins have improved cardiovascular outcomes: Lessons from randomized trials and observational studies of real-world practice in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 17-27.	2.2	8
227	Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry. <i>American Heart Journal</i> , 2020, 225, 88-96.	1.2	8
228	Identifying Patients for Nonstatin Therapy. <i>Reviews in Cardiovascular Medicine</i> , 2018, 19, S1-S8.	0.5	8
229	Family history of myocardial infarction predicts incident coronary heart disease in postmenopausal women with diabetes: the Women's Health Initiative Observational Study. <i>Diabetes/Metabolism Research and Reviews</i> , 2009, 25, 725-732.	1.7	7
230	Big Data Cohort Extraction to Facilitate Machine Learning to Improve Statin Treatment. <i>Western Journal of Nursing Research</i> , 2017, 39, 42-62.	0.6	7
231	Development of a comprehensive health-risk prediction tool for postmenopausal women. <i>Menopause</i> , 2019, 26, 1385-1394.	0.8	7
232	Effects of menopausal hormone therapy on erythrocyte ω -3 and ω -6 PUFA concentrations in the Women's Health Initiative randomized trial. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 1700-1706.	2.2	7
233	Producing personalized statin treatment plans to optimize clinical outcomes using big data and machine learning. <i>Journal of Biomedical Informatics</i> , 2022, 128, 104029.	2.5	7
234	Identifying Patients for Nonstatin Therapy. <i>Reviews in Cardiovascular Medicine</i> , 2018, 19, 1-8.	0.5	7

#	ARTICLE	IF	CITATIONS
235	Cholesterol Management: Targeting a Lower Low-Density Lipoprotein Cholesterol Concentration Increases Adult Treatment Panel-III Goal Attainment. <i>American Journal of Cardiology</i> , 2006, 97, 1667-1669.	0.7	6
236	Is a statin as part of a poly pill the answer?. <i>Current Atherosclerosis Reports</i> , 2009, 11, 15-22.	2.0	6
237	Patterns of type 2 diabetes monitoring in rural towns: How does frequency of HbA1c and lipid testing compare with existing guidelines?. <i>Australian Journal of Rural Health</i> , 2016, 24, 371-377.	0.7	6
238	Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Geriatric Ischemic Stroke Patients: Are the Rates Right?. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	6
239	Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial. <i>Journal of Clinical Lipidology</i> , 2020, 14, 707-719.	0.6	6
240	A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies. <i>Cardiology and Therapy</i> , 2020, 9, 447-465.	1.1	6
241	A Uniform Approach to Modeling Risk Factor Relationships for Ischemic Lesion Prevalence and Extent: The Women's Health Initiative Magnetic Resonance Imaging Study. <i>Neuroepidemiology</i> , 2010, 34, 55-62.	1.1	5
242	Statin use and risk of haemorrhagic stroke in a community-based cohort of postmenopausal women: an observational study from the Women's Health Initiative. <i>BMJ Open</i> , 2015, 5, e007075-e007075.	0.8	5
243	Chronic Use of Aspirin and Total White Matter Lesion Volume: Results from the Women's Health Initiative Memory Study of Magnetic Resonance Imaging Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 2128-2136.	0.7	5
244	Serum lipid changes following the onset of depressive symptoms in postmenopausal women. <i>Psychiatry Research</i> , 2017, 247, 282-287.	1.7	5
245	Long-Term Trends in Hypertension and Elevated Blood Pressure Among U.S. Adults, 1999 to 2016. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2089-2091.	1.2	5
246	Lipid update 2020 - Introduction and foreword. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 373-374.	1.6	5
247	Low LDL-C Levels. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2294-2296.	1.2	5
248	Contemporary Evidence-Based Guidelines. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1176-1182.	1.4	4
249	The future of lipid guidelines. <i>Current Opinion in Lipidology</i> , 2016, 27, 585-591.	1.2	4
250	Haptoglobin Genotype as a Determinant of Benefit or Harm From Niacin for Participants With Diabetes. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2553-2554.	1.2	4
251	Genetic predisposition to elevated levels of C-reactive protein is associated with a decreased risk for preeclampsia. <i>Hypertension in Pregnancy</i> , 2017, 36, 30-35.	0.5	4
252	Roundtable discussion: Dietary fats in prevention of atherosclerotic cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2018, 12, 574-582.	0.6	4

#	ARTICLE	IF	CITATIONS
253	Risk Patterns and Mortality in Postmenopausal Women Using Latent Class Analysis. <i>American Journal of Preventive Medicine</i> , 2021, 61, e225-e233.	1.6	4
254	Impact of Cyclooxygenase Inhibitors in the Women's Health Initiative Hormone Trials: Secondary Analysis of a Randomized Trial. <i>PLOS Clinical Trials</i> , 2006, 1, e26.	3.5	3
255	Statin Pleiotropy: A Popular Concept but Clinical Significance Unclear. <i>Cardiovascular Drugs and Therapy</i> , 2007, 21, 81-83.	1.3	3
256	LDL reduction: How low should we go and is it safe?. <i>Current Cardiology Reports</i> , 2008, 10, 481-487.	1.3	3
257	Benefits associated with achieving optimal risk factor levels for the primary prevention of cardiovascular disease in older men. <i>Journal of Clinical Lipidology</i> , 2012, 6, 58-65.	0.6	3
258	Low Birth Weight and Risk of Later-Life Physical Disability in Women. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 72, glw134.	1.7	3
259	Testing for type 2 diabetes in Indigenous Australians: guideline recommendations and current practice. <i>Medical Journal of Australia</i> , 2017, 207, 206-210.	0.8	3
260	Optimizing Statins and Ezetimibe in Guideline-Focused Management. <i>Cardiology Clinics</i> , 2018, 36, 221-223.	0.9	3
261	Changes in physical and mental health are associated with cardiovascular disease incidence in postmenopausal women. <i>Age and Ageing</i> , 2019, 48, 448-453.	0.7	3
262	A Comparison of NCEP and Absolute Risk Stratification Methods for Lipid-Lowering Therapy in Middle-Aged Adults: The ARIC Study. <i>Preventive Cardiology</i> , 2001, 4, 148-157.	1.1	2
263	Comparison of effectiveness and safety of simvastatin in patients <75 versus ≥75 years of age with coronary, cerebral, or peripheral arterial disease. <i>American Journal of Cardiology</i> , 2002, 90, 994-995.	0.7	2
264	Response to Letter Regarding Article, "Optimism, Cynical Hostility, and Incident Coronary Heart Disease and Mortality in the Women's Health Initiative". <i>Circulation</i> , 2010, 121, e408.	1.6	2
265	Statins and Primary Prevention of Cardiovascular Disease in Women. <i>American Journal of Lifestyle Medicine</i> , 2015, 9, 114-129.	0.8	2
266	Potential for Net Benefit Should Guide Preventive Therapy. <i>Circulation</i> , 2017, 135, 630-632.	1.6	2
267	Planning a Research Agenda to Incorporate Imaging Into Clinical Practice. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 1039-1041.	2.3	2
268	Multi-ancestry genome-wide association study accounting for gene-psychosocial factor interactions identifies novel loci for blood pressure traits. <i>Human Genetics and Genomics Advances</i> , 2021, 2, 100013.	1.0	2
269	Patient perceptions and use of non-statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry. <i>Clinical Cardiology</i> , 2021, 44, 863-870.	0.7	2
270	Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl. <i>PLoS ONE</i> , 2020, 15, e0240166.	1.1	2

#	ARTICLE	IF	CITATIONS
271	How low to target LDL?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2006, 2, 414-415.	2.9	1
272	Achievement of Specified Lipid and High-Sensitivity C-Reactive Protein Levels with Statin-Ezetimibe Versus Statin in Male and Female Patients Using Combined Data from 22,913 Patients. <i>Journal of Clinical Lipidology</i> , 2010, 4, 200-201.	0.6	1
273	In search of self-awareness: Results of the National Lipid Association 2010 Lipid Pulse Membership Survey. <i>Journal of Clinical Lipidology</i> , 2011, 5, 12-17.	0.6	1
274	NLA Recommendations for the Diagnosis and Management of Familial Hypercholesterolemia in Children and Adults. <i>Journal of Clinical Lipidology</i> , 2011, 5, S2-S3.	0.6	1
275	Treatment effect of alirocumab according to age group, smoking status, and hypertension: Pooled analysis from 10 randomized ODYSSEY studies. <i>Journal of Clinical Lipidology</i> , 2019, 13, 735-743.	0.6	1
276	Perils of Observational Data Analyses. <i>Journal of the American Heart Association</i> , 2019, 8, e012490.	1.6	1
277	The neuropsychology of statin intolerance. <i>Nature Reviews Cardiology</i> , 2021, 18, 153-154.	6.1	1
278	A Population-Based Study of Simvastatin Drug-Drug Interactions in Cardiovascular Disease Patients. <i>AMIA Summits on Translational Science Proceedings</i> , 2020, 2020, 664-673.	0.4	1
279	Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006-2012). <i>Journal of Thrombosis and Thrombolysis</i> , 2021, , 1.	1.0	1
280	Sharon Monteith, <i>Advancing Sisterhood?: Interracial Friendships in Contemporary Southern Fiction</i> (Athens: the University of Georgia Press, 2000, \$40). Pp. 241. <sc>ISBN</sc> 0 8203 2249 0.. <i>Journal of American Studies</i> , 2002, 36, 513-570.	0.1	0
281	Managing cholesterol in the elderly. <i>Aging Health</i> , 2006, 2, 623-638.	0.3	0
282	How Low to Go for Primary Prevention?. <i>Current Cardiovascular Risk Reports</i> , 2010, 4, 245-247.	0.8	0
283	Is there a future for CETP-inhibitor therapy?. <i>Clinical Investigation</i> , 2011, 1, 367-370.	0.0	0
284	Age, Abdominal Obesity, and Baseline High-Sensitivity C-Reactive Protein Are Associated with Low-Density Lipoprotein Cholesterol, non-HDL Cholesterol, and ApoB Responses to Lipid-Lowering Therapy in Patients with Metabolic Syndrome and Moderately High/High Coronary Heart Disease Risk. <i>Journal of Clinical Lipidology</i> , 2012, 6, 290-291.	0.6	0
285	Identification and Treatment of Women with Familial Hypercholesterolemia. <i>Current Cardiovascular Risk Reports</i> , 2012, 6, 196-204.	0.8	0
286	Can We Vaccinate Against Atherosclerosis and Prevent Cardiovascular Disease?. <i>Current Cardiovascular Risk Reports</i> , 2013, 7, 249-250.	0.8	0
287	Statins vs Early Hormone Therapy for the Primary Prevention of Cardiovascular Disease in Women. <i>Current Cardiovascular Risk Reports</i> , 2013, 7, 163-165.	0.8	0
288	Coronary Heart Disease in Women & Men: Similar and Different. <i>Current Cardiovascular Risk Reports</i> , 2013, 7, 423-424.	0.8	0

#	ARTICLE	IF	CITATIONS
289	ETC-1002 Lowers LDL-Cholesterol and Beneficially Modulates Other Cardio-Metabolic Risk Factors in Hypercholesterolemic Subjects. Journal of Clinical Lipidology, 2013, 7, 283.	0.6	0
290	Lipids in Women. , 2013, , 965-974.		0
291	Reply. Journal of the American College of Cardiology, 2014, 64, 1761.	1.2	0
292	Overview of 2013 American College of Cardiology/American Heart Association cholesterol guideline for reducing cardiovascular risk. Clinical Practice (London, England), 2014, 11, 273-275.	0.1	0
293	Statins for Primary Prevention in Adults Aged 75 Years or Older. Annals of Internal Medicine, 2015, 163, 481.	2.0	0
294	Letter by Robinson Regarding Articles, "Bringing Back Targets to IMPROVE™ Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?" and "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT." Circulation, 2016, 133, e461.	1.6	0
295	Reply. Journal of the American College of Cardiology, 2017, 69, 1996.	1.2	0
296	What Women (and Clinicians) Don't Know Hurts Them —. Journal of the American College of Cardiology, 2017, 70, 133-135.	1.2	0
297	Primary Prevention of Atherosclerotic Cardiovascular Disease. , 2018, , 433-458.		0
298	Meta-analysis of LDL-C Lowering and Mortality—Reply. JAMA - Journal of the American Medical Association, 2018, 320, 1493.	3.8	0
299	The Call for Precision Health Trials in Older Adults. Journal of the American College of Cardiology, 2018, 71, 2537-2539.	1.2	0
300	PATIENT PERCEPTIONS AND MANAGEMENT OF CHOLESTEROL AMONG INDIVIDUALS WITH OR WITHOUT DIABETES IN COMMUNITY PRACTICE: RESULTS FROM THE PALM REGISTRY. Journal of the American College of Cardiology, 2019, 73, 1710.	1.2	0
301	STATIN THERAPY IN PATIENTS WITH CEREBROVASCULAR DISEASE VERSUS CORONARY ARTERY DISEASE: INSIGHTS FROM THE PALM REGISTRY. Journal of the American College of Cardiology, 2019, 73, 1747.	1.2	0
302	Genetic Risk Scores for Maternal Lipid Levels and Their Association with Preterm Birth. Lipids, 2019, 54, 641-650.	0.7	0
303	PRACTICE-LEVEL VARIATION IN STATIN USE AND LDL-C CONTROL IN THE UNITED STATES: RESULTS FROM THE PATIENT AND PROVIDER ASSESSMENT OF LIPID MANAGEMENT (PALM) REGISTRY. Journal of the American College of Cardiology, 2019, 73, 1706.	1.2	0
304	The next treatment paradigm in cardiovascular prevention?. Lancet, The, 2019, 394, 2129-2131.	6.3	0
305	Management of Elevated Low-Density Lipoprotein Cholesterol. Fundamental and Clinical Cardiology, 2006, , 255-294.	0.0	0
306	Title is missing!. , 2020, 15, e0240166.		0

#	ARTICLE	IF	CITATIONS
307	Title is missing!. , 2020, 15, e0240166.		0
308	Title is missing!. , 2020, 15, e0240166.		0
309	Title is missing!. , 2020, 15, e0240166.		0
310	Access to PCSK9 Inhibitors. Reviews in Cardiovascular Medicine, 2018, 19, 47-50.	0.5	0